SCHEMBL14978283

SCHEMBL14978283

CC(C)(C)OC(=O)NC[C@@]1(c2ccc(Br)cc2)NC(=O)NC1=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.39
RECQL P46063 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
FPR3 P25089 6/20 0.38
FPR2 P25090 6/20 0.38
ADAM17 P78536 2/20 0.37
ADAMTS5 Q9UNA0 2/20 0.37
ADAMTS4 O75173 1/20 0.37
MMP2 P08253 1/20 0.37
MMP3 P08254 1/20 0.37
MMP13 P45452 1/20 0.37
MMP14 P50281 1/20 0.37
CTSS P25774 1/20 0.37
CTSK P43235 1/20 0.37
ALDH1A1 P00352 1/20 0.35
MAPT P10636 1/20 0.35
DRD2 P14416 1/20 0.35
AAK1 Q2M2I8 2/20 0.35
MAPK10 P53779 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5955565 0.88 MMP14 (0.40) ADAM17ADAMTS5ADAMTS4MMP2MMP3
SCHEMBL5955764 0.86 ADAM17 (0.44) SMN1; SMN2ADAM17ADAMTS5ADAMTS4MMP2
SCHEMBL29873860 0.86 MMP13 (0.43) ADAM17ADAMTS5ADAMTS4MMP2MMP3
SCHEMBL23367190 0.86 MMP13 (0.43) ADAM17ADAMTS5ADAMTS4MMP2MMP3
SCHEMBL10200265 0.81 EPHX2 (0.35) ADAM17ADAMTS5ADAMTS4MMP2MMP3
SCHEMBL29874400 0.80 CYP3A4 (0.52) ADAM17ADAMTS5ADAMTS4MMP2MMP13
SCHEMBL24938581 0.80 CYP3A4 (0.52) ADAM17ADAMTS5ADAMTS4MMP2MMP13
SCHEMBL14417733 0.77 ADAM17 (0.43) ADAM17ADAMTS5ADAMTS4MMP2MMP3
SCHEMBL24927725 0.77 ADAMTS7 (0.34) ADAM17ADAMTS5ADAMTS4MMP2MMP3
SCHEMBL29979689 0.77 ADAMTS7 (0.34) ADAM17ADAMTS5ADAMTS4MMP2MMP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1976849-B1 COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS MERCK SHARP & DOHME (US) 2016-03-09 EP disclosed
US-8450355-B2 Compounds for the treatment of inflammatory diseases MERCK SHARP & DOHME CORP. (US) 2013-05-28 US disclosed
US-8450355-B2 Compounds for the treatment of inflammatory diseases MERCK SHARP & DOHME CORP. (US) 2013-05-28 US disclosed
US-20110288077-A1 COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISEASES SCHERING CORPORATION (US) 2011-11-24 US disclosed
US-20110288077-A1 COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISEASES SCHERING CORPORATION (US) 2011-11-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110288077-A1 COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISEASES TNF, ADAMTS13, MMP11 NPC1 548/4885RECQL 2945/4885RAB9A 881/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.